2-(2-Oxo-2-(p-tolyl)ethyl)malononitrile, 95.0%, 1g

5-(1-ETHYL-1H-PYRAZOL-4-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE, 95.0%, 250mg

(S)-BENZYL 2-METHYL-4-OXOPIPERIDINE-1-CARBOXYLATE, 95.0%, 500mg

6-Bromo-1-nitronaphthalene, 95.0%, 1g

(R)-2,6-Dibromo-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide, 97%, 5g

Isopropyl Ether (stabilized with HQ)>98.0%(GC)500mL

1-(5-methyl-2-pyridinyl)ethanone, 95.0%, 10g

(4-(N-Methylsulfamoyl)phenyl)boronic acid, 97.0%, 5g

Methyl 5-fluoro-2-(2-(1-methyl-1H-1,2,4-triazol-5-yl)acetyl)-3-nitrobenzoate hydrochloride, 98%, 100mg

8-benzyl-4-(pyridine-3-carbonyl)-1-oxa-4,8-diazaspiro[4.5]decane-3-carboxylic acid, 95.0%, 1g

6-Bromo-8-methyl-[1,2,4]triazolo[4,3-a]pyridine, 98%, 5g

2-Methoxyethane-1-sulfonyl fluoride, 97%, 5g

Colonna capillare per GC ROTI®Cap-1, 25 m, 0.20 mm, 0.20 µm, 1 Pezzo(i)